ASLN ASLAN Pharmaceuticals Limited

3.3
+0.11  (+3%)
Previous Close 3.19
Open 3.21
Price To Book 2.56
Market Cap 105764340
Shares 32,049,800
Volume 3,499
Short Ratio
Av. Daily Volume 28,603

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due 2H 2019.
Varlitinib - TREETOP
Biliary tract cancer
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Varlitinib
Gastric cancer
Phase 2 interim data presented at ASH December 2018 - noted 4/8 patients showed signs of efficacy.
ASLAN002
Acute Myeloid Leukemia (AML)
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer